Submitted by Biogen
Diversity makes us stronger and helps drive innovation. We’re proud of the progress we’ve made in advancing our diversity, equity, and inclusion commitments. We also know that we have much more to do, and we are in it for the long haul.
Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, neuropsychiatry, specialized immunology and rare diseases and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.
More from Biogen